Norwich Loses US Vyvanse Appeal – But Patents Run Course In August
Blockbuster ADHD Drug Set To Face Competition, 16 Years Post Launch
US-based Norwich Pharmaceuticals has lost its bid to move several months early on US competition to Takeda’s Vyvanse ADHD blockbuster.